^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tevimbra (tislelizumab-jsgr)

    i
    Company:
    BeiGene
    Drug class:
    PD1 inhibitor
    Related drugs:
    Apply
    A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (AdvanTIG-206) (NCT04948697)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    08/20/2021
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) (NCT05152147)
    Phase 3
    Jazz Pharmaceuticals
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/02/2021
    Primary completion :
    05/15/2025
    Completion :
    05/15/2026
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)
    SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. (NCT06835179)
    Phase 2
    The First Affiliated Hospital with Nanjing Medi...
    Not yet recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/01/2025
    Primary completion :
    02/01/2027
    Completion :
    05/01/2027
    BRAF
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer (BGB-A317-214) (NCT05116085)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/26/2022
    Primary completion :
    09/26/2023
    Completion :
    01/01/2027
    MSI
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr)
    A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (NCT05904496)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/19/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    TMB • MSI
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (BGB-900-102) (NCT03744468)
    Phase 1/2
    BeiGene
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    11/13/2018
    Primary completion :
    02/06/2025
    Completion :
    02/06/2025
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma (RATIONALE 305) (NCT03777657)
    Phase 3
    BeiGene
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    12/13/2018
    Primary completion :
    02/28/2023
    Completion :
    08/27/2024
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (HFB-200603-01) (NCT05789069)
    Phase 1
    HiFiBiO Therapeutics
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    05/09/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • HFB200603
    CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA (NCT05299476)
    Phase 2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    04/16/2022
    Primary completion :
    01/20/2025
    Completion :
    06/01/2025
    HER-2 • PD-L1
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma (NCT05532059)
    Phase 2
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/31/2022
    Primary completion :
    08/31/2025
    Completion :
    08/31/2028
    PD-L1
    |
    cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma (NCT05823311)
    Phase 3
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    09/01/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    PD-L1
    |
    cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) (RATIONALE-303) (NCT03358875)
    Phase 3
    BeiGene
    Completed
    Last update posted :
    02/10/2025
    Initiation :
    11/30/2017
    Primary completion :
    07/15/2021
    Completion :
    01/18/2024
    PD-L1
    |
    PD-L1 expression
    |
    docetaxel • Tevimbra (tislelizumab-jsgr)
    First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer (NCT05586061)
    Phase 2
    Qilu Hospital of Shandong University
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/10/2023
    Primary completion :
    12/29/2024
    Completion :
    12/31/2025
    HER-2
    |
    Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)
    Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (BGB-A317-A445-101) (NCT04215978)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    01/30/2020
    Primary completion :
    01/24/2025
    Completion :
    01/24/2025
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A445
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (NCT05544929)
    Phase 1
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/26/2022
    Primary completion :
    02/20/2026
    Completion :
    02/20/2026
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115
    Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors (ACROPOLI) (NCT04802876)
    Phase 2
    SOLTI Breast Cancer Research Group
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/12/2021
    Primary completion :
    09/30/2025
    Completion :
    03/31/2027
    PD-1
    |
    PD-1 expression
    |
    Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)
    Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) (NCT05431270)
    Phase 1/2
    Phanes Therapeutics
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    08/11/2022
    Primary completion :
    12/01/2027
    Completion :
    08/01/2028
    CD73
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • docetaxel • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (BGB-LC-201) (NCT05635708)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    03/07/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • alcestobart (LBL-007)
    Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (AdvanTIG-203) (NCT04732494)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    01/31/2025
    Initiation :
    03/31/2021
    Primary completion :
    02/01/2023
    Completion :
    12/26/2023
    PD-L1
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma (NCT05937438)
    Phase 1/2
    Anhui Provincial Hospital
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/01/2023
    Primary completion :
    09/30/2025
    Completion :
    12/31/2026
    PD-L1
    |
    AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (BGB-HNSCC-201) (NCT05909904)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    01/08/2025
    Initiation :
    07/21/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (Liberty-201) (NCT05609370)
    Phase 1/2
    BeiGene
    Active, not recruiting
    Last update posted :
    01/01/2025
    Initiation :
    01/29/2023
    Primary completion :
    04/15/2026
    Completion :
    04/15/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • alcestobart (LBL-007)
    Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (BGB-LC-202) (NCT05577702)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    12/18/2024
    Initiation :
    02/16/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • alcestobart (LBL-007)
    Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) (NCT06728618)
    Phase 2
    Shanghai Zhongshan Hospital
    Not yet recruiting
    Last update posted :
    12/11/2024
    Initiation :
    12/01/2024
    Primary completion :
    05/01/2026
    Completion :
    03/01/2028
    TMB • MSI
    |
    PD-L1 expression
    |
    Erbitux (cetuximab) • cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (NCT05526924)
    Phase 1
    University of Chicago
    Recruiting
    Last update posted :
    11/22/2024
    Initiation :
    03/07/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    PD-L1 • PD-1
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    Tislelizumab with Azacitidine in the Treatment of R/R AML (NCT06586099)
    Phase 1/2
    Institute of Hematology & Blood Diseases Hospit...
    Withdrawn
    Last update posted :
    09/19/2024
    Initiation :
    10/05/2024
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    PD-L1
    |
    Tevimbra (tislelizumab-jsgr) • azacitidine
    Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC (NCT06573398)
    Phase 2
    Ruijin Hospital
    Not yet recruiting
    Last update posted :
    08/27/2024
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    CD8 • CD163 • CD4 • CD68 • CD86
    |
    Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Zadaxin (thymalfasin)
    A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer (NCT06471673)
    Phase 1/2
    BriaCell Therapeutics Corporation
    Recruiting
    Last update posted :
    08/26/2024
    Initiation :
    05/29/2024
    Primary completion :
    04/30/2025
    Completion :
    10/30/2025
    PD-L1 • PD-L2 • PRAME
    |
    Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Bria-OTS
    Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC (NCT06456138)
    Phase 1/2
    Shanghai Chest Hospital
    Not yet recruiting
    Last update posted :
    06/13/2024
    Initiation :
    07/01/2024
    Primary completion :
    06/30/2026
    Completion :
    12/31/2028
    KRAS
    |
    Mekinist (trametinib) • Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)
    A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer (NCT04294160)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/22/2020
    Primary completion :
    10/11/2024
    Completion :
    10/11/2024
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • naporafenib (ERAS-254) • batoprotafib (TNO155) • rineterkib (LTT462)
    Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (BGB-A317-3111-10188-101) (NCT04282018)
    Phase 1/2
    BeiGene
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/25/2020
    Primary completion :
    05/06/2025
    Completion :
    12/31/2025
    MSI
    |
    MSI-H/dMMR
    |
    paclitaxel • Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib) • BGB-10188
    Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01) (NCT04699188)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    02/24/2021
    Primary completion :
    01/08/2027
    Completion :
    01/08/2027
    KRAS
    |
    KRAS mutation
    |
    Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • batoprotafib (TNO155) • opnurasib (JDQ443)
    A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (AdvanTIG-302) (NCT04746924)
    Phase 3
    BeiGene
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    06/08/2021
    Primary completion :
    04/01/2026
    Completion :
    10/01/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (NCT05935098)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    08/21/2023
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    CCR8
    |
    PD-L1 expression • CCR8 expression
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC (NCT05878028)
    Phase 2
    Quanli Gao
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    09/16/2022
    Primary completion :
    09/15/2025
    Completion :
    09/15/2025
    EGFR • ROS1
    |
    docetaxel • Tevimbra (tislelizumab-jsgr)
    Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (AdvanTIG-205) (NCT05014815)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    11/16/2021
    Primary completion :
    10/01/2024
    Completion :
    10/01/2024
    PD-L1
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors (RATIONALE-209) (NCT03736889)
    Phase 2
    BeiGene
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    09/19/2018
    Primary completion :
    11/01/2026
    Completion :
    09/01/2027
    MSI
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr)
    Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer (mRCAT) (NCT05972655)
    Phase 2
    Sir Run Run Shaw Hospital
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    08/02/2023
    Primary completion :
    05/01/2025
    Completion :
    05/01/2026
    MSI • MSH6 • MSH2
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (NCT05142696)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    07/13/2022
    Primary completion :
    05/05/2025
    Completion :
    05/03/2028
    SSTR
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (HFB-200301-01) (NCT05238883)
    Phase 1
    HiFiBiO Therapeutics
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    03/10/2022
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    BRAF
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • HFB200301
    Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction (NCT06394791)
    Phase 1/2
    The First Affiliated Hospital with Nanjing Medi...
    Not yet recruiting
    Last update posted :
    05/01/2024
    Initiation :
    05/01/2024
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    IL2
    |
    Tevimbra (tislelizumab-jsgr)